FDA approves Depomed’s urinary tract treatment

	Tweet

Specialty drugmaker Depomed Inc. Friday said the U.S. Food and Drug Administration approved its extended-release antibiotic Proquin XR as a treatment for urinary tract infections, making it the company’s first approved product.

The once-daily, extended-release formulation of ciprofloxacin hydrochloride is the first version of Bayer’s antibiotic Cipro to list nausea and diarrhea as “uncommon” adverse events in its label, rather than “common” adverse events, Depomed said.

In contrast to Cipro and its generic equivalents that release their entire dosage within about 30 minutes, Proquin XR releases its full dosage over 6 hours, avoiding large dosages hitting the intestinal tract all at once.

Even once-daily Cipro XR releases its dosage within about 2 hours, the company said.

Depomed said it is in negotiations with potential marketing partners.

Shares of Depomed rose 63 cents to $4.70 on the Inet electronic network, up from a close of $4.07 on Thursday on Nasdaq. 

RELATED STORIES:
Treating vaginosis doesn’t prevent preterm birth   Premature death less likely than end stage renal disease for African-Americans with kidney disease   Dialysis Patients Who Fall Have Added Mortality Risk   Ankle position may help control incontinence in women   Clinic-Owner Urologists Perform More Surgeries Than Peers   Penile surgery effective for neurologic impairment   Millions of Americans in early stages of kidney disease need stroke monitoring   New Statistical Method Shows Importance of Dialysis Dose   Getting married may also get you a kidney   Statins May Protect Against Kidney Complications Following Elective Surgery   Study Shows Advantages of Robotic Surgery for Kidney Condition   New Clinical Trial to Examine Ways to Improve Treatment of Uterine Fibroids

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]